{"id":31321,"date":"2025-04-07T17:53:14","date_gmt":"2025-04-07T09:53:14","guid":{"rendered":"https:\/\/flcube.com\/?p=31321"},"modified":"2025-04-07T17:53:15","modified_gmt":"2025-04-07T09:53:15","slug":"duality-biotherapeutics-makes-hong-kong-ipo-debut-with-adc-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31321","title":{"rendered":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline"},"content":{"rendered":"\n

China-based Duality Biotherapeutics, Inc. (HKG: 9606<\/a>) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company’s growth and development.<\/p>\n\n\n\n

Company Overview<\/strong>
Duality Biotherapeutics, a specialist in antibody-drug conjugates (ADCs), has established a robust pipeline of 12 innovative and differentiated ADC molecules since its founding in 2019. The company is advancing an autoimmune ADC candidate expected to enter clinical trials between 2024 and 2026. Duality Bio’s technological prowess is underpinned by four proprietary ADC platforms: DITAC, DIBAC, DIMAC, and DUPAC.<\/p>\n\n\n\n

IPO Journey<\/strong>
Duality Bio’s IPO journey began with its first filing to the HKSE in August 2023. Despite a setback when the prospectus was deemed invalid on February 26, 2024, the company received endorsement from the China Securities Regulatory Commission (CSRC) for overseas listing in January 2024, fulfilling the necessary preconditions for a listing committee hearing with the HKSE.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial…<\/p>\n","protected":false},"author":1,"featured_media":31322,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3795,3974,72],"class_list":["post-31321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-duality-biotherapeutics","tag-hkg-9606","tag-ipo"],"yoast_head":"\nDuality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31321\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline\" \/>\n<meta property=\"og:description\" content=\"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31321\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T09:53:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T09:53:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline\",\"datePublished\":\"2025-04-07T09:53:14+00:00\",\"dateModified\":\"2025-04-07T09:53:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321\"},\"wordCount\":182,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0715-png.webp\",\"keywords\":[\"Duality Biotherapeutics\",\"HKG: 9606\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31321#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31321\",\"name\":\"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0715-png.webp\",\"datePublished\":\"2025-04-07T09:53:14+00:00\",\"dateModified\":\"2025-04-07T09:53:15+00:00\",\"description\":\"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31321\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0715-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0715-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31321#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline - Insight, China's Pharmaceutical Industry","description":"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31321","og_locale":"en_US","og_type":"article","og_title":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline","og_description":"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.","og_url":"https:\/\/flcube.com\/?p=31321","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-07T09:53:14+00:00","article_modified_time":"2025-04-07T09:53:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31321#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31321"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline","datePublished":"2025-04-07T09:53:14+00:00","dateModified":"2025-04-07T09:53:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31321"},"wordCount":182,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31321#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","keywords":["Duality Biotherapeutics","HKG: 9606","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31321#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31321","url":"https:\/\/flcube.com\/?p=31321","name":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31321#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31321#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","datePublished":"2025-04-07T09:53:14+00:00","dateModified":"2025-04-07T09:53:15+00:00","description":"China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial public offering (IPO) of 15,071,600 shares on the Hong Kong Stock Exchange (HKSE). The shares were priced at HKD 103.2 (USD 13.2) each, raising a total of HKD 1.555 billion (USD 200 million). This milestone marks a significant step in the company's growth and development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31321#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31321"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31321#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","width":1080,"height":608,"caption":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31321#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0715-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31321"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31321\/revisions"}],"predecessor-version":[{"id":31323,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31321\/revisions\/31323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31322"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}